Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study

go back to reference Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA (2022) Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:167–192. https://doi.org/10.6004/jnccn.2022.0008CrossRefPubMed Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA (2022) Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:167–192. https://​doi.​org/​10.​6004/​jnccn.​2022.​0008CrossRefPubMed

go back to reference Chen Y, He J, Liu D, Xiao J, Chen X, Tang H, Luo D, Shang C, Lian L, Peng J (2021) Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis. BMC Cancer 21:1328. https://doi.org/10.1186/s12885-021-09093-9CrossRefPubMedPubMedCentral Chen Y, He J, Liu D, Xiao J, Chen X, Tang H, Luo D, Shang C, Lian L, Peng J (2021) Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis. BMC Cancer 21:1328. https://​doi.​org/​10.​1186/​s12885-021-09093-9CrossRefPubMedPubMedCentral

go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://​doi.​org/​10.​1016/​j.​ejca.​2008.​10.​026CrossRefPubMed

go back to reference Global Burden of Disease Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abdulle ASM, Abebe ND, Abraha HN, Abu-Raddad LJ, Abualhasan A, Adedeji IA, Advani SM, Afarideh M, Afshari M, Aghaali M, Agius D, Agrawal S, Ahmadi A, Ahmadian E, Ahmadpour E, Ahmed MB, Akbari ME, Akinyemiju T, Al-Aly Z, AlAbdulKader AM, Alahdab F, Alam T, Alamene GM, Alemnew BTT, Alene KA, Alinia C, Alipour V, Aljunid SM, Bakeshei FA, Almadi MAH, Almasi-Hashiani A, Alsharif U, Alsowaidi S, Alvis-Guzman N, Amini E, Amini S, Amoako YA, Anbari Z, Anber NH, Andrei CL, Anjomshoa M, Ansari F, Ansariadi A, Appiah SCY, Arab-Zozani M, Arabloo J, Arefi Z, Aremu O, Areri HA, Artaman A, Asayesh H, Asfaw ET, Ashagre AF, Assadi R, Ataeinia B, Atalay HT, Ataro Z, Atique S, Ausloos M, Avila-Burgos L, Avokpaho E, Awasthi A, Awoke N, Ayala Quintanilla BP, Ayanore MA, Ayele HT, Babaee E, Bacha U, Badawi A, Bagherzadeh M, Bagli E, Balakrishnan S, Balouchi A, Barnighausen TW, Battista RJ, Behzadifar M, Behzadifar M, Bekele BB, Belay YB, Belayneh YM, Berfield KKS, Berhane A, Bernabe E, Beuran M, Bhakta N, Bhattacharyya K, Biadgo B, Bijani A, Bin Sayeed MS, Birungi C et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 5:1749–1768. https://doi.org/10.1001/jamaoncol.2019.2996CrossRef Global Burden of Disease Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abdulle ASM, Abebe ND, Abraha HN, Abu-Raddad LJ, Abualhasan A, Adedeji IA, Advani SM, Afarideh M, Afshari M, Aghaali M, Agius D, Agrawal S, Ahmadi A, Ahmadian E, Ahmadpour E, Ahmed MB, Akbari ME, Akinyemiju T, Al-Aly Z, AlAbdulKader AM, Alahdab F, Alam T, Alamene GM, Alemnew BTT, Alene KA, Alinia C, Alipour V, Aljunid SM, Bakeshei FA, Almadi MAH, Almasi-Hashiani A, Alsharif U, Alsowaidi S, Alvis-Guzman N, Amini E, Amini S, Amoako YA, Anbari Z, Anber NH, Andrei CL, Anjomshoa M, Ansari F, Ansariadi A, Appiah SCY, Arab-Zozani M, Arabloo J, Arefi Z, Aremu O, Areri HA, Artaman A, Asayesh H, Asfaw ET, Ashagre AF, Assadi R, Ataeinia B, Atalay HT, Ataro Z, Atique S, Ausloos M, Avila-Burgos L, Avokpaho E, Awasthi A, Awoke N, Ayala Quintanilla BP, Ayanore MA, Ayele HT, Babaee E, Bacha U, Badawi A, Bagherzadeh M, Bagli E, Balakrishnan S, Balouchi A, Barnighausen TW, Battista RJ, Behzadifar M, Behzadifar M, Bekele BB, Belay YB, Belayneh YM, Berfield KKS, Berhane A, Bernabe E, Beuran M, Bhakta N, Bhattacharyya K, Biadgo B, Bijani A, Bin Sayeed MS, Birungi C et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 5:1749–1768. https://​doi.​org/​10.​1001/​jamaoncol.​2019.​2996CrossRef

go back to reference Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodera Y (2022) A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer 25:619–628. https://doi.org/10.1007/s10120-022-01286-wCrossRefPubMedPubMedCentral Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodera Y (2022) A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer 25:619–628. https://​doi.​org/​10.​1007/​s10120-022-01286-wCrossRefPubMedPubMedCentral

go back to reference In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T (2018) The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer 21:1–9. https://doi.org/10.1007/s10120-017-0765-yCrossRefPubMed In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T (2018) The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer 21:1–9. https://​doi.​org/​10.​1007/​s10120-017-0765-yCrossRefPubMed

go back to reference Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40. https://doi.org/10.1016/S0140-6736(21)00797-2CrossRefPubMedPubMedCentral Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40. https://​doi.​org/​10.​1016/​S0140-6736(21)00797-2CrossRefPubMedPubMedCentral

go back to reference Japanese Gastric Cancer A (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14: 101–112. https://doi.org/10.1007/s10120-011-0041-5 Japanese Gastric Cancer A (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14: 101–112. https://​doi.​org/​10.​1007/​s10120-011-0041-5

go back to reference Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH (2021) PRODIGY: a phase III study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol 39:2903–2913. https://doi.org/10.1200/JCO.20.02914CrossRefPubMedPubMedCentral Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH (2021) PRODIGY: a phase III study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol 39:2903–2913. https://​doi.​org/​10.​1200/​JCO.​20.​02914CrossRefPubMedPubMedCentral

go back to reference Kumagai Y, Futoh Y, Miyato H, Ohzawa H, Yamaguchi H, Saito S, Kurashina K, Hosoya Y, Lefor AK, Sata N, Kitayama J (2022) Effect of systemic or intraperitoneal administration of anti-PD-1 antibody for peritoneal metastases from gastric cancer. In Vivo 36:1126–1135. https://doi.org/10.21873/invivo.12811 Kumagai Y, Futoh Y, Miyato H, Ohzawa H, Yamaguchi H, Saito S, Kurashina K, Hosoya Y, Lefor AK, Sata N, Kitayama J (2022) Effect of systemic or intraperitoneal administration of anti-PD-1 antibody for peritoneal metastases from gastric cancer. In Vivo 36:1126–1135. https://​doi.​org/​10.​21873/​invivo.​12811

go back to reference Li T, Chen L (2011) Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 14:104–106PubMed Li T, Chen L (2011) Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 14:104–106PubMed

go back to reference Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M (2021) Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 9:513. https://doi.org/10.21037/atm-21-434 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M (2021) Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 9:513. https://​doi.​org/​10.​21037/​atm-21-434

go back to reference Lin JX, Xu YC, Lin W, Xue FQ, Ye JX, Zang WD, Cai LS, You J, Xu JH, Cai JC, Tang YH, Xie JW, Li P, Zheng CH, Huang CM (2021) Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer: a nonrandomized controlled trial. JAMA Netw Open 4:e2116240. https://doi.org/10.1001/jamanetworkopen.2021.16240CrossRefPubMedPubMedCentral Lin JX, Xu YC, Lin W, Xue FQ, Ye JX, Zang WD, Cai LS, You J, Xu JH, Cai JC, Tang YH, Xie JW, Li P, Zheng CH, Huang CM (2021) Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer: a nonrandomized controlled trial. JAMA Netw Open 4:e2116240. https://​doi.​org/​10.​1001/​jamanetworkopen.​2021.​16240CrossRefPubMedPubMedCentral

go back to reference Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R (2020) Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. https://doi.org/10.3390/ijms21114012CrossRefPubMedPubMedCentral Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R (2020) Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. https://​doi.​org/​10.​3390/​ijms21114012CrossRefPubMedPubMedCentral

go back to reference Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Perol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E (2017) The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol 12:194–207. https://doi.org/10.1016/j.jtho.2016.10.003CrossRefPubMed Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Perol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E (2017) The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol 12:194–207. https://​doi.​org/​10.​1016/​j.​jtho.​2016.​10.​003CrossRefPubMed

go back to reference Quesada S, Samalin E, Thezenas S, Khellaf L, Mourregot A, Portales F, Mazard T, Ychou M, Adenis A (2022) Perioperative FOLFOX in patients with locally advanced oesogastric adenocarcinoma. Anticancer Res 42:185–193. https://doi.org/10.21873/anticanres.15472 Quesada S, Samalin E, Thezenas S, Khellaf L, Mourregot A, Portales F, Mazard T, Ychou M, Adenis A (2022) Perioperative FOLFOX in patients with locally advanced oesogastric adenocarcinoma. Anticancer Res 42:185–193. https://​doi.​org/​10.​21873/​anticanres.​15472

go back to reference Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D (2016) Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol 10:887–892. https://doi.org/10.1080/17474124.2016.1209407CrossRefPubMed Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D (2016) Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol 10:887–892. https://​doi.​org/​10.​1080/​17474124.​2016.​1209407CrossRefPubMed

go back to reference Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T, Shi M, Xu W, Zhu Z, Liu W, Yan C, Li C, Liu B, Yan M, Zhu Z (2020) Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun 11:6093. https://doi.org/10.1038/s41467-020-19965-6CrossRefPubMedPubMedCentral Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T, Shi M, Xu W, Zhu Z, Liu W, Yan C, Li C, Liu B, Yan M, Zhu Z (2020) Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun 11:6093. https://​doi.​org/​10.​1038/​s41467-020-19965-6CrossRefPubMedPubMedCentral

go back to reference Scott LJ (2018) Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs 78:747–758. https://doi.org/10.1007/s40265-018-0903-9CrossRefPubMed Scott LJ (2018) Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs 78:747–758. https://​doi.​org/​10.​1007/​s40265-018-0903-9CrossRefPubMed

go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://​doi.​org/​10.​3322/​caac.​21660CrossRefPubMed

go back to reference Tang Z, Wang Y, Yu Y, Cui Y, Liang L, Xu C, Shen Z, Shen K, Wang X, Liu T, Sun Y (2022) Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Med 20:107. https://doi.org/10.1186/s12916-022-02309-0CrossRefPubMedPubMedCentral Tang Z, Wang Y, Yu Y, Cui Y, Liang L, Xu C, Shen Z, Shen K, Wang X, Liu T, Sun Y (2022) Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Med 20:107. https://​doi.​org/​10.​1186/​s12916-022-02309-0CrossRefPubMedPubMedCentral

go back to reference Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH (2021) The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (lond) 41:747–795. https://doi.org/10.1002/cac2.12193CrossRefPubMed Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH (2021) The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (lond) 41:747–795. https://​doi.​org/​10.​1002/​cac2.​12193CrossRefPubMed

go back to reference Wang X, Zhao DB, Yang L, Chi Y, Zhao H, Jiang LM, Jiang J, Tang Y, Li N, Liu WY, Dou LZ, Zou SM, Xue LY, Ren JS, Tian YT, Che X, Guo CG, Bai XF, Sun YM, Wang SL, Song YW, Liu YP, Fang H, Li YX, Jin J (2022) Preoperative concurrent chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: phase II randomized study. Front Oncol 12:870741. https://doi.org/10.3389/fonc.2022.870741CrossRefPubMedPubMedCentral Wang X, Zhao DB, Yang L, Chi Y, Zhao H, Jiang LM, Jiang J, Tang Y, Li N, Liu WY, Dou LZ, Zou SM, Xue LY, Ren JS, Tian YT, Che X, Guo CG, Bai XF, Sun YM, Wang SL, Song YW, Liu YP, Fang H, Li YX, Jin J (2022) Preoperative concurrent chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: phase II randomized study. Front Oncol 12:870741. https://​doi.​org/​10.​3389/​fonc.​2022.​870741CrossRefPubMedPubMedCentral

go back to reference Wang T, Wang N, Zhou H, Zhou A, Jin J, Chen Y, Zhao D (2020) Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection. Transl Cancer Res 9:529–535. https://doi.org/10.21037/tcr.2019.11.37 Wang T, Wang N, Zhou H, Zhou A, Jin J, Chen Y, Zhao D (2020) Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection. Transl Cancer Res 9:529–535. https://​doi.​org/​10.​21037/​tcr.​2019.​11.​37

go back to reference Wei Q, Yuan X, Li J, Xu Q, Ying J (2020) PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study. Transl Cancer Res 9:5315–5322. https://doi.org/10.21037/tcr-20-1333 Wei Q, Yuan X, Li J, Xu Q, Ying J (2020) PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study. Transl Cancer Res 9:5315–5322. https://​doi.​org/​10.​21037/​tcr-20-1333

go back to reference Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X (2022) Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer. https://doi.org/10.1136/jitc-2022-004656CrossRefPubMedPubMedCentral Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X (2022) Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer. https://​doi.​org/​10.​1136/​jitc-2022-004656CrossRefPubMedPubMedCentral

go back to reference Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18:60. https://doi.org/10.1186/s12943-019-0974-6CrossRefPubMedPubMedCentral Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18:60. https://​doi.​org/​10.​1186/​s12943-019-0974-6CrossRefPubMedPubMedCentral

go back to reference Zhang Y, Zhang B, Yang J, Zhang J, Zhang W (2021) Perioperative safety and effectiveness of neoadjuvant therapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel plus apatinib in locally advanced gastric cancer. Cancer Manag Res 13:2279–2286. https://doi.org/10.2147/CMAR.S304093CrossRefPubMedPubMedCentral Zhang Y, Zhang B, Yang J, Zhang J, Zhang W (2021) Perioperative safety and effectiveness of neoadjuvant therapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel plus apatinib in locally advanced gastric cancer. Cancer Manag Res 13:2279–2286. https://​doi.​org/​10.​2147/​CMAR.​S304093CrossRefPubMedPubMedCentral

go back to reference Zheng Y, Wang Z, Yan C, Yan M, Hou Z, Zheng R, Zhu Z, Li C (2020) Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Ann Transl Med 8:1684. https://doi.org/10.21037/atm-20-7802 Zheng Y, Wang Z, Yan C, Yan M, Hou Z, Zheng R, Zhu Z, Li C (2020) Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Ann Transl Med 8:1684. https://​doi.​org/​10.​21037/​atm-20-7802

go back to reference Zhu ZG (2021) Current status and prospect of perioperative therapy for locally advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 24:101–106. https://doi.org/10.3760/cma.j.cn.441530-20210105-00003CrossRefPubMed Zhu ZG (2021) Current status and prospect of perioperative therapy for locally advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 24:101–106. https://​doi.​org/​10.​3760/​cma.​j.​cn.​441530-20210105-00003CrossRefPubMed